Gilead Sciences, Inc. (GILD – Free Report) just released its third-quarter 2017 financial results, posting earnings of $2.06 per share and revenues of $6.51 billion. Currently, GILD is a Zacks Rank #3 (Hold) and is down over 2.40% to $76 per share in after-hours trading shortly after its earnings report was released.
GILD:
Missed earnings estimates. The company posted earnings of $2.06 per share, missing the Zacks Consensus Estimate of $2.09 per share.
Beat revenue estimates. The company saw revenue figures of $6.51 billion, beating our consensus estimate of $6.33 billion.
Gilead Sciences revenues fell over 13% from $7.50 billion in the year-ago period. On top of that, the company’s earnings tanked over 17% after posting earnings of $2.49 per share in its third-quarter of 2016.
The company’s third-quarter product sales fell from $7.4 billion to $6.4 billion.
Here’s a graph that looks at GILD’s Price, Consensus and EPS Surprise history:
Gilead Sciences, Inc. Price, Consensus and EPS Surprise
Gilead Sciences, Inc. Price, Consensus and EPS Surprise | GILD
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.
